Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule...
34 insider sale filings on record · latest filing 2026-09-08.
No open-market insider purchases (SEC Form 4 code P) on record for CTNM.